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Topic 02 – Heart failure and cardiomyo-
pathy 
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Our aim was to investigate the safety and feasibility of transendocardial
injections guided by 3-dimensional NogaStar XP mapping of autologous bone
marrow-derived mesenchymal stromal cells (MSC) in patients with chronic
myocardial ischemia and left ventricular dysfunction.
The MESAMI 1 trial is a bicentric phase 1 study, including 10 patients
with chronic myocardial ischemia. The inclusion criteria were: NYHA Class
II-IV and/or angina pectoris CCS Class III or IV, chronic ischemic cardiomy-
opathy with LVEF ≤35%, optimal medical and revascularization therapies,
and reversible perfusion defect by SPECT. Bone marrow was obtained by
aspiration from the iliac crest and MSC were expanded in culture for 17 days.
Transendocardial injections (n=14-16) of autologous bone marrow MSC were
made into viable muscle in border zones of left ventricular scar. Bone marrow
volume was 16.8±2.0ml, and patients received 61.5*106 MSC. After 1-month
follow-up (FU), the primary end-point of safety and feasibility was met since
all patients tolerated the procedure with no adverse events due to the proce-
dure and the cell therapy product. Secondary endpoints between baseline and
3-month FU showed a significant decreased of summed stress score measured
by SPECT from 34.1±8 to 25.3±9.5(p<0.05). This effect was not maintained
at 12 months (32.1±8.0, NS). The echocardiographic LVEF improved signifi-
cantly of more than 6% from 29.4±6.5% to 35.9±6.7% (p<0.001) at 3 months
and was maintained up to 12-month FU (35.7±8.1%; p<0.001). Others para-
meters including NYHA, 6-minute walk test, VO2 peak, and Quality of life
(Qol) showed a trend toward improvement at 3 months compared to baseline
and up to 12 months except for Qol.
We demonstrated the safety and the feasibility of this innovative treatment.
A randomized, double blind, multicenter, placebo-controlled clinical trial
(MESAMI 2) will evaluate the efficiency of this procedure in a larger popula-
tion.Clinical Trial Registration: NCT01076920
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Background: Cardiac involvement is frequent in systemic light chain
amyloidosis (AL). Left-sided valvular thickening (LVT) have been described
in AL reflecting heavy infiltration of the valvular endocardium by amyloid
proteins. However, the exact prevalence at diagnosis and the prognostic
significance of LVT in AL patients have never been investigated.
Aims: to study the prevalence and the impact on long-term survival LVT
in AL patients.
Methods and results: Between 1998 and 2013, 150 AL patients were
included at diagnosis (mean age was 68±11 ans, 59% were male). A compre-
hensive transthoracic echocardiography was performed at baseline. The pres-
ence of LVT was assessed visually and was found in 42% of patients. Compared
to patients without LVT, those with LVT have more frequently advanced
NYHA functional class. They also had significantly higher left ventricular (LV)
wall thickening (p=0.01), LV mass (p=0.02), and mitral E/e’ (p=0.0009) and
larger left atrial size (p<0.0001). Moreover, patients with advanced Mayo Clinic
stage more frequently had LVT: 58%, 45%, and 5% in stage III, II, and I respec-
tively (p<0.0001). Patients with severe symptoms more frequently exhibited
LVT (63% in NYHA III-IV vs. 33% in NYHA I-II, p=0.0008). During a mean
follow-up of 2.9±3 years, 79 deaths occurred (53%). The presence of LVT was
significantly associated with reduced 1 and 5-year survival: 51±4% vs. 70±4%
and 32±7% vs. 64±6% respectively (p=0.0002). In multivariate analysis, after
adjustment for age, gender, NYHA class≥III, clearance of creatininemia, and
LV ejection fraction, LVT remained an independant significant marker of mor-
tality (Hazard ratio= 1.9, 95%CI: 1.10-3.34, p=0.02).
Conclusion: The presence of LVT is a common finding in patients with
AL and is associated with impaired both LV systolic and diastolic function,
poorer functional status and advanced stage of the disease. In addition, LVT
appeared as a powerful marker of mortality.
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Objective: To evaluate longitudinal and radial left ventricular (LV) dys-
synchrony in patients with left ventricular hypertrophy (LVH), and to compare
abnormalities associated with hypertrophic cardiomyopathy (HCM) and LVH
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second to hypertensive heart disease (HLVH) using 2D speckle tracking
imaging.
Methods: 2D fort chamber long-axis and basal, middle, and apical
short-axis of LV images were acquired in 97patients with LVH including
67 with HCM and 30 with HLVH, and in 30 age-matched controls. Radial
strain, longitudinal strain, time interval from the R-wave to peak radial
strain (Trs), and time to peak longitudinal strain (Tls) were measured in
six equidistant segments at each level of the 3 LV short-axis and 4C long-
axis views using 2D speckle tracking analysis. To assess LV dys-
synchrony, Trs (rs)-18SD, the standard deviation (SD) of Tls (ls) was
calculated.
Results: Regional radial strain in the middle and apical short-axis seg-
ments was significantly less in patients with HCM than in those with HHD
(56%±23 VS 45%±21 and 47%±19 VS 38%±17respectevely, p<0.01 ).
Regional longitudinal basal strain was also less in HCM (–13±3.3% VS –17±
2.9%, p=0.002). Trs-18SD and Tls were significantly longer in patients with
HCM than in age-matched controls and patients with HLVH (Trs-18SD:
HCM: 68±22ms, HHD: 21±11ms, control: 15±12ms P < 0.001, Tls – : HCM:
7 – ±12ms, HHD: 44±11ms, control: 33±13ms P < 0.001).
Conclusions: The presence of LVH is thus not always associated with LV
dyssynchrony. However, the greater reduction of regional strain and severe
LV dyssynchrony in HCM may contribute to the adverse cardiovascular out-
comes associated with this disease. 
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Background: Breast cancer is the most frequent female cancer. Treat-
ment of HER2+ tumours evolved with immunotherapy, leading to
improved survival. Cardiac toxicity associated to trastuzumab is frequent
but reversible in 75% of cases. However, only little is know about the
cardiotoxicity of new anti-VEGF antibodies associated to trastuzumab. In
this study, we aimed to assess the cardiac tolerance of bevacizumab asso-
ciated with trastuzumab and chemotherapy in HER2+ breast cancer
patients. 
Methods and results: This is a post-hoc analysis of the BEVERLY-2
study, aiming to assess the efficacy of neoadjuvant bevacizumab, trastu-
zumab, and chemotherapy for primary inflammatory HER2+ breast cancer.
A cohort of 52 patients was prospectively included. Left ventricular ejection
fraction (LVEF) was assessed by echocardiography and/or isotopic ventric-
ulography every three months during the mean follow-up of 33±3,42
months. Mean age prior to chemotherapy was 49,75 years ±11,60. On inclu-
sion, mean LVEF was 66,56±6,13.There was no significant difference
between LVEF on inclusion and before the 5th cycle of chemotherapy fifth
cycle (C5)(66,56%±6,13 vs 65,11%±7,68 ; p=0,24) ,whereas LVEF was sig-
nificantly reduced at the end of the neoadjuvant therapy (62,07%±7,84 vs
66,56±6,13; p=0,0001). The nadir of LVEF was 57,87%±8,79 and occured
generally during the adjuvant period. In 16 patients, LVEF decreased below
50% after neoadjuvant therapy but complete recovery of LVEF was
observed in all at the end of the follow-up, 3 months after the end of the
treatment (Figure 1, next page). 
Conclusion: In this study, with an effective treatment protocol for inflam-
matory breast cancer, reduction in LVEF was observed in 30% of patients,
however, it was reversible in all. Nadir of LVEF was observed after the final
adjuvant therapy (31%). This timing and the possibility of recovery should be
considered when discussing the interruption of chemotherapy because of
reduced LVEF during the follow up. 
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Hereditary heart diseases are typically characterized by autosomal domi-
nant inheritance and delayed cardiac expression. Predictive genetic testing is
offered to asymptomatic relatives to allow targeted medical care with early
therapeutics in order to reduce the risk of complications (sudden death, heart
failure). Psychological and sociological issues related to predictive testing are
however complex and have been poorly studied. Predictive genetic testing is
performed in our multidisciplinary out-patient clinic dedicated to cardio-
genetics since 1999. 
To evaluate our practices regarding predictive genetic testing for hereditary
heart diseases and study the behavior of relatives after pre-test consultation
(information phase), especially regarding a waiting period that was offered
before blood sampling. 
We retrospectively studied records from 304 consecutive relatives seen in
our department and have requested predictive genetic testing. Underlying
diseases in the families were HCM (60%), DCM (17%), ARVC (15%), LQT
(5%), Brugada syndrome (2%) and other (1%). A total of 21 different genes
were analyzed and most frequent ones were MYBPC3 (97), MYH7 (77),
LMNA (37), PKP2 (29) and TNNT2 (16). There were 260 adults and
44 minors. At the time of the first consultation, the average age was 37 years,
and 83% of the relatives previously had a cardiac checkup (echocardiography
for 71%). 
After first multidisciplinary consultation, 22 relatives (8%) dropped out of
procedure (did not performed blood sampling) and 11 relatives (3%) per-
formed blood sampling but did not come back to know their results. Blood
sample was delayed for 70% of relatives and immediate for 30%. A mutation
was present in 36% of relatives (leading to careful follow-up and cascade
screening in offspring) and absent in 64% (they were reassured and discharged
from clinic).
We observed a high level of genetic uptake after initial consultation but a
minority of relatives decided to stop or delay the procedure. These results sug-
gest the benefit of a waiting period before blood sampling and illustrate the
importance of a multidisciplinary team in this setting. 
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This study assessed the long-term outcome of heart (HTx) and heart-lung
transplantation (HLTx) in patients with congenital heart disease (CHD) and
children with non-congenital cardiac or pulmonary disease.
Methods: Retrospective single-centre analysis of long-term posttransplant
outcome, with chart collection of clinical and paraclinical data.
Results: From 1984 to 2013, 111 first-HTx, 5 HLTx and 6 re-HTx
were performed (62males), in patients aged 11.7±8.2y: 96(79%) aged
<18y. Cardiopathy included 61 cardiomyopathies (50.8%), 50 CHD
(41.7%), 6 retransplants (5%). HLTx included 1 Eisenmenger, 1 PPHT,
and 2 pulmonary diseases. Patients with cardiomyopathy were younger
than CHD (8.7y vs 14.9y).Seventeen (14%) patients had circulatory
mechanical support as bridge to transplant. Acute rejection occurred more
frequently within the first year post-transplant or > 5thyear in non-com-
pliant teenagers. Overall 33 patients died (27%), 3.5±4.6y postTx (1 day
